PD-1/PD-L1免疫抑制剂在食管癌新辅助治疗中的研究进展

Research Progress of PD-1/PD-L1 Inhibitors in Neoimmunoadjuvant Therapy of Esophageal Cancer

摘要: 食管癌(Esophageal cancer, EC)是我国常见的消化道恶性肿瘤，其发病率及死亡率呈逐年上升趋势。手术、放疗和化疗是目前食管癌的主要治疗方式。虽取得了一定的临床疗效，但患者的总体预后仍不理想。以PD-1/PD-L1抑制剂为主的免疫治疗成为当前食管癌治疗的焦点，并肯定了其疗效和安全性，随着更多临床预后结果的公布，免疫疗法与现有治疗模式的结合势必是食管癌治疗的最佳策略。本文就PD-1/PD-L1免疫抑制剂免疫治疗食管癌最新研究进展予以综述。

Abstract: Esophageal cancer is a common malignant tumor of digestive tract in China, and its incidence and mortality are increasing year by year. Surgery, radiotherapy and chemotherapy are the main treatment modalities for esophageal cancer at present, which have achieved some clinical efficacy, but the overall prognosis of patients remains unsatisfactory. Immunotherapy based on PD-1/PD-L1 immunosuppressive agents became the focus of current therapy for esophageal cancer, and their efficacy and safety have been affirmed. As more clinical prognostic results are published, the combination of immunotherapy and existing treatment modes is bound to be the optimal strategy for esophageal cancer treatment. In this article, the recent research progress of PD-1/PD-L1 immunosuppressant immunotherapy for esophageal cancer is reviewed.